SINCE THE development of the conception of specific anticonvulsant drugs and of methods of testing anticonvulsant activity in animals1 a long list of new medicines has been introduced into clinical practice for the control of epilepsy. It includes diphenylhydantoin U. S. P. (phenytoin, Dilantin), methylphenylethylhydantoin (Mesantoin), phenacemide (Phenurone), trimethadione U. S. P. (Tridione), paramethadione (Paradione), phethenylate (Thiantoin), and glutamic acid. Others not yet on the market are under investigation, and of course phenobarbital is still a strong contender. Almost alone among recent authors, Arieff2 maintains 12% of his patients on bromides, and 73% are seizure-free. Even the ketogenic diet is still used,3 and interest in the use of surgical measures has widened.4
The practitioner, and even the specialist, is apt to find himself confused by this plethora, and reference to the literature is not particularly helpful. Usually an investigator who wishes to try a new drug
PUTNAM TJ, ROTHENBERG SF, BERCEL NA. RAPID DETERMINATION OF OPTIMUM MEDICATION IN RECALCITRANT CASES OF EPILEPSY. AMA Arch NeurPsych. 1954;72(2):169–179. doi:10.1001/archneurpsyc.1954.02330020037004
Customize your JAMA Network experience by selecting one or more topics from the list below.